Drug intelligence / Profile preview

CARBOTOX

Development stage: Unknown
Lead developer: Imuna Pharm
Modality: Small Molecules
Administration: Oral

Overview

CARBOTOX is an approved medical product developed and manufactured by Imuna Pharm in Slovakia. It is a combination therapy consisting of activated charcoal (320 mg) and sodium thiosulphate, formulated as oral tablets. Activated charcoal functions as an adsorbent, binding various toxic substances and gases within the gastrointestinal tract to prevent their systemic absorption. Sodium thiosulphate acts as a neutralizing agent for specific poisons and exerts a mild laxative effect to assist in the evacuation of the digestive tract. CARBOTOX is indicated for the treatment of acute diarrhea, food poisoning, irritable bowel syndrome, ulcerative colitis, and gastritis, and is also utilized in diagnostic imaging of the gallbladder and bile ducts.

Brand names: CARBOTOX

Beyond the preview

Go deeper on CARBOTOX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CARBOTOX.

Explore the full profile